CDA and myelodysplastic syndrome: Recently, a combination of the CDA inhibitor (4R)-2′-deoxy-2′,2′-difluoro-3,4,5,6-tetrahydrouridine (cedazuridine, Ib, Figure 1B) with the anticancer drug decitabine was approved as an oral pill (i.e., C-DEC or ASTX727) for the treatment of patients with intermediate or high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia (CMML) [8].